Breaking News

Adimab Expands Collaborations with Merck and Lilly

January 8, 2013

Adimab has expanded its research collaborations with Merck and Lilly. The new agreement provides Merck with expanded access to its technology to identify human antibody candidates, including potentially bispecific antibody candidates across all disease areas. Adimab will discover therapeutic antibody candidates to multiple targets selected by Merck for a three-year period. Adimab will receive upfront payments and is eligible to receive preclinical and clinical development milestones, as well as royalties on product sales.
 
Additionally, Adimab has expanded its research agreement with Lilly to include the discovery and optimization of multiple bispecific antibodies targeting molecular targets identified by Lilly.
 
“We are always pleased when our existing partners choose to expand their relationship with us,” said Tillman Gerngross, Adimab’s chief executive officer and co-founder. “The antibody discovery arena has become very competitive and nothing is more validating than existing partners coming back for broader access to our platform.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent